Company / Cash & Equivalents
Pasithea Therapeutics Corp. Cash & Equivalents History
FY2021-FY2022 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$33.1M
FY2022
5-year range
$33.1M / $53.0M
FY2021-FY2022
Trend
-37.4%
vs FY2021
Sector context
Sector data unavailable
Latest sector comparison
What the data says
$33M in FY2022.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2022, cash & equivalents decreased 37.4% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -3.26 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2022 | $33.1M | -37.4% |
| FY2021 | $53.0M | - |
As of FY2022 · SEC 10-K · Updated Jun 28, 2026